Back to Journals » Journal of Asthma and Allergy » Volume 14

Optimal Management of Hereditary Angioedema: Shared Decision-Making

Authors Banerji A, Anderson J, Johnston DT

Received 13 October 2020

Accepted for publication 18 December 2020

Published 9 February 2021 Volume 2021:14 Pages 119—125

DOI https://doi.org/10.2147/JAA.S284029

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Luis Garcia-Marcos


Video abstract presented by Aleena Banerji.

Views: 87

Aleena Banerji,1 John Anderson,2 Douglas T Johnston3

1Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, USA; 2Clinical Research Center of Alabama, Birmingham, AL, USA; 3Asthma and Allergy Specialists, Charlotte, NC, USA

Correspondence: Aleena Banerji 6 Aaron Road, Lexington, MA, 02421, USA
Tel +1-617-308-5975
Fax +1-617-724-0239
Email ABANERJI@mgh.harvard.edu

Abstract: All patients with hereditary angioedema (HAE) must have access to on-demand therapy to treat attacks and may benefit from prophylactic therapy to reduce the attack frequency. Treatment decisions should be individualized, based on patient preferences and needs. One method for facilitating individualized therapy is shared decision-making (SDM), a widely used methodology for making treatment decisions among multiple therapeutic options. We propose a three-phase “ 3D” model (Discover, Discuss, Decide) for SDM in HAE. The Discover phase focuses on improving the physician’s understanding of the patient’s needs and understanding of the available therapeutic choices. The Discuss phase considers the alternatives, allowing a collaborative, informed treatment selection in the Decision phase. The 3D model is an ongoing, iterative process based on the patient’s changing needs and response to therapy. Uncovering the patient’s therapy goals through appropriate questions during these phases can help uncover relevant information for treatment selection information. SDM based on the 3D model can be a beneficial tool for optimizing therapy in HAE.

Keywords: prophylaxis, hereditary angioedema, individualized therapy, patient preference, on-demand therapy, adherence, quality of life, shared decision-making

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]